<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>技术 on Illiterate&#39;s blog</title>
    <link>https://blog.illiterate.info/categories/%E6%8A%80%E6%9C%AF/</link>
    <description>Recent content in 技术 on Illiterate&#39;s blog</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 09 Mar 2021 10:50:18 +0800</lastBuildDate><atom:link href="https://blog.illiterate.info/categories/%E6%8A%80%E6%9C%AF/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Chapter 9 Development of PD Biomarker for PhI Trials</title>
      <link>https://blog.illiterate.info/posts/ch9_development-of-pd-biomarker-for-phi-trials/</link>
      <pubDate>Tue, 09 Mar 2021 10:50:18 +0800</pubDate>
      
      <guid>https://blog.illiterate.info/posts/ch9_development-of-pd-biomarker-for-phi-trials/</guid>
      <description>PD biomarkers are molecular indicators of the drug’s effect on the target in an organism
  Based on the understanding of molecular biology of cancer and the role of the tumor environment
  Can be used to examine the link between a drug treatment, the target effects, and a biological tumor response
  for selecting the optimal population
  Usually lack of standardization and validation
  Growing interest in PD biomarkers in phase I</description>
    </item>
    
    <item>
      <title>Chapter 7 Attribution and Management of Toxicities in PhI Trials</title>
      <link>https://blog.illiterate.info/posts/ch7_attribution-and-management-of-toxicities-in-phi-trials/</link>
      <pubDate>Tue, 09 Mar 2021 10:25:18 +0800</pubDate>
      
      <guid>https://blog.illiterate.info/posts/ch7_attribution-and-management-of-toxicities-in-phi-trials/</guid>
      <description>In clinical research, attribution is the determination of whether a clinical event is related to the investigational treatment under study, or non-treatment causes, such as the underlying disease, or comorbidities. it is also referred to as “relatedness to study treatment” in published reports or as “causality” in certain regulatory contexts
 In early-stage development, the use of attribution data is for safety assessment to ensure patient protection In later stages of development, the safety profile of an investigational drug is usually completed with key toxicities of special interest and less attention is paid to mild and expected adverse events  There are different causality reporting requirements between the FDA and EMA</description>
    </item>
    
    <item>
      <title>Chapter 8 Incorporating PK Into Oncology Ph1 Trials</title>
      <link>https://blog.illiterate.info/posts/ch8_strategies-for-incorporating-pk-into-oncology-ph1-trials/</link>
      <pubDate>Mon, 08 Mar 2021 16:05:18 +0800</pubDate>
      
      <guid>https://blog.illiterate.info/posts/ch8_strategies-for-incorporating-pk-into-oncology-ph1-trials/</guid>
      <description>Basic premise: free drug concentration at the target tissue of action will determine the magnitude and the duration of drug response
phase 1 enzymes metabolism: through the processes of oxidation, reduction or carboxylation
phase 2 enzymes conjugate make the phase 1 metabolites more water soluble
key objectives for collecting PK from FiH trials
 To discern the given dose and schedule provide effective level of systemic exposure To evaluate PK/PD variability To assess the relationship between exposure and toxicity&amp;amp;efficacy To predict DDI  Key elements of bioanalytical methods</description>
    </item>
    
    <item>
      <title>Chapter 3 Preclinical Studies to Enable First in Human Trials</title>
      <link>https://blog.illiterate.info/posts/ch3_preclinical-studies-to-enable-first-in-human-trials/</link>
      <pubDate>Mon, 08 Mar 2021 14:58:42 +0800</pubDate>
      
      <guid>https://blog.illiterate.info/posts/ch3_preclinical-studies-to-enable-first-in-human-trials/</guid>
      <description>Preclinical genomic data
- https://depmap.org/portal/
- https://www.sanger.ac.uk/
- https://cansarblack.icr.ac.uk/
Key steps in pre-clinical drug discovery before FiH   Target selection
  Target validation based on
  ​ - Biological assessment
​ - Technical assessment
  Strategy for obtaining hit matter
  Establishment of a screening cascade
  Defining appropriate pharmaceutical properties
  ​ - Drug candidate selection
 Establishing a Target Product Profile  Target selection  derived from published data that implicate  ​ - particular mutation</description>
    </item>
    
    <item>
      <title>Chapter 2 Paradigms in Cancer Drug Development</title>
      <link>https://blog.illiterate.info/posts/ch2_paradigms-in-cancer-drug-development-a-universe-with-many-galaxies/</link>
      <pubDate>Fri, 05 Mar 2021 15:57:57 +0800</pubDate>
      
      <guid>https://blog.illiterate.info/posts/ch2_paradigms-in-cancer-drug-development-a-universe-with-many-galaxies/</guid>
      <description>Milestones of the different paradigm shifts in the timeline of oncology EDD Main differences between four established paradigms in oncology early drug development Cytotoxic Chemotherapeutics (CHTs)  Both efficacy and toxicity show sigmoid dose-response relationship - Underlying assumption: the mechanism resulting in toxicity is similar to the mechanism leading to efficacy Tumor growth follow Gompertzian function  less time between treatments likely more efficient dose regime, dose, timing, duration, and schedule, matters   Find therapeutic window  Conventionally, 1/10 of 10% lethal dose (LD10) in mice or 1/6 of the highest NOAEL in non-rodent Accelerated titration designs advocate for single-patient cohorts at early dose levels   ADC (antibody- drug conjugate) considerations  Rational selection of target antigens, expressed in normal cells at very low levels Careful modification of the mAb (e.</description>
    </item>
    
    <item>
      <title>Chapter 1 Drug Development Perspective</title>
      <link>https://blog.illiterate.info/posts/ch1_the-development-of-a-drug-a-pharmaceutical-drug-development-perspective/</link>
      <pubDate>Fri, 05 Mar 2021 15:50:26 +0800</pubDate>
      
      <guid>https://blog.illiterate.info/posts/ch1_the-development-of-a-drug-a-pharmaceutical-drug-development-perspective/</guid>
      <description>Critical steps enabling early development Reducing attrition biomedical approaches
  leverage pre-existing information including bioinformatics approaches
  integrating non-clinical information to predict clinical properties of NME
  optimize the operational costs to gain timely information in early trials
  non-clinical pharmacokinetic (PK) studies   PK profile in animals is first used to optimize subsequent formulation
  support non-clinical pharmacology and toxicology studies
  pharmacokinetic/pharmacodynamic (PK/PD) models to design</description>
    </item>
    
    <item>
      <title>上海电信光猫下多个无线路由组网</title>
      <link>https://blog.illiterate.info/posts/homenetwork/</link>
      <pubDate>Mon, 25 Jan 2021 15:06:25 +0800</pubDate>
      
      <guid>https://blog.illiterate.info/posts/homenetwork/</guid>
      <description>缘起 数月前入手(keng)了一台威联通的NAS，准备作为资料统一备份用。没时间也不想折腾，直接连上家里的网络就开始了备份。郁闷的是，网络的传输速度最快才能达到10M/s。就这样，忍受了很长一段时间，也备份了大概好几个TB的文件。
这次，由于疫情的原因，原定去三亚的度假计划就这么被无情的取消了。正好腾出时间优(zhe)化(teng)一下家里的网络了。
仔细梳理了一下，现在家里有3个网段，主要设备分布在家里的三个房间，见下图：
很明显，台式机访问NAS时要经过多次网络地址转换（Network Address Translation，NAT）。这应该时内网传输慢的根本原因。ps. 由于客厅只有一个网络接口，之前已经用电力猫将IPTV分离出来，给NAS一个独立网络接口。否则会更慢。
还有一些物理限制：
 光猫在卧室1，直接连上路由的话，无线的信号会很差。加之弱电箱容量有限，无法将路由和光猫放一起。 各房间的有线网络从弱电箱中连出，其中只有卧室2有两个相邻有线接口。 客厅中的IPTV和NAS需放在一起，方便以后通过HDMI直接看NAS上的视频。 路由器和两台小一点的存储设备(Mao &amp;amp; Bai)，因为IPTV旁的地方有限，无法和NAS放在一起。只能放在客厅远离IPTV的有线网络接口附近。  现在想达到的要求是：
 家里联网的设备都尽量连在同一个网段内。 物尽其用，无必要不购买新设备。 在原来的基础上，改动越少越好。  花开 在网上学习了一堆网络知识，终于厘清了头绪。重点是：
 将光猫信号连接到卧室2的主路由(AX3)后，再连接回卧室2的交换机。 AX3的性能强，将作为主路由。客厅的路由作为辅助路由。具体参考 多台无线路由能不能同名无缝切换？。重点如下：  1. 找性能最强的做主路由, 因为这一台路由会负责所有的DHCP. 预留几个IP给辅助路由器, 不要全部DHCP出去. 例如DHCP范围设成192.168.1.10~192.168.1.225. 预留192.168.1.2~92. 辅助的路由和主路由链好, 链接是LAN&amp;lt;-&amp;gt;LAN (不是LAN&amp;lt;-&amp;gt;WAN).3. 辅助路由要关闭WAN, 关闭DHCP. 路由IP手动设成 192.168.1.X. 就是第一步预留段.4. 辅助的路由SSID和无线密码, 密码制式全部都要一模一样. 不要一个WAP2 一个WPA的. 这样就应该可以了.更详细的设置见路由器有线桥接的两种方式异同
修改后的网络图
担心：
 两个路由器之间的LAN&amp;lt;-&amp;gt;LAN连接中间有一个交换机，是否会出现问题？没问题 外部访问的流量全部通过R2S软路由，是否稳定？是否可以作为旁路由? 旁路由更佳  理想的网络状态是大部分上网的流量不经过软路由，需要KX上网的设备才经过软路由，减少软路由的负荷。
于是，旁路由的方案应该是最佳方案。只需要修改KX上网的设备的网关（和DNS? 下面设置为主路由的IP）即可！
花落 花了2天的时间分别尝试了上面两种网络部署，总结如下：
 极路由作为客厅辅助路由并不理想，连接到上面的设备IP地址仍然是 192.168.199.x，而且极路由的网口无法和设备进行有线连接。目前是用另一台交换机连接极路由和网络存储设备。计划再入一个华为AX3用Mesh组网，取代这里的交换机和极路由，彻底解决。Mesh组网确实好用！ R2S旁路由设置：提醒：重启后 WAN和LAN口只有一个连在主路由上，可能需要分别插上网线后ping一下新的网关地址（此处：192.</description>
    </item>
    
    <item>
      <title>用hugo结合github建立个人静态网站</title>
      <link>https://blog.illiterate.info/posts/buildsite/</link>
      <pubDate>Thu, 14 Jan 2021 14:38:08 +0800</pubDate>
      
      <guid>https://blog.illiterate.info/posts/buildsite/</guid>
      <description>hugo生成静态网页 安装hugo  访问Github下载Hugo的应用程序，下载地址 https://github.com/gohugoio/hugo/releases windows请选择下载hugo_0.xx.0_Windows-64bit.zip 下载完成止之后解压文件至C:\Windows\system32，若其他路径需添加到系统环境变量Path中 打开CMD，执行 hugo version 命令验证是否安装成功  C:\Users\XXXXXX&amp;gt;hugo versionHugo Static Site Generator v0.80.0-792EF0F4 windows/amd64 BuildDate: 2020-12-31T13:37:57Z本地hugo目录  新建/指定本地目录，通过hugo把站点生成到该目录下 （CMD中） $ hugo new site E:/website/second-blog 命令执行后查看E:/website/second-blog目录，查看文件目录结构。  │ config.toml│├─archetypes│ default.md│├─content├─data├─layouts├─static└─themes安装git  从git官网 https://git-scm.com/downloads/ 下载 安装git  安装hugo主题  下载一个主题并加载到config.toml文件中 （CMD中）  git clone https://github.com/yihui/hugo-ivy.git
通过在 config.toml 配置使用：theme = &amp;ldquo;hugo-ivy&amp;rdquo;  另一种方法（未尝试）： 下载一个主题并加载到config.toml文件中：
git initgit submodule add https://github.</description>
    </item>
    
  </channel>
</rss>
